The athletic performance guide covers fueling strategies for active individuals using peptide protocols
The first animal studies showing that GLP-1 potentially had effects on the CV system was published in 2002, and the first study to show cardioprotection was in 2008 (102, 211), but it was not until the LEADER cardiovascular outcomes trial (CVOT) with liraglutide, published in 2016, that a reduction in CV risk with a GLP-1RA was documented (100)
By synthesizing current evidence, this review aims to clarify the potential role of HPA axis dysregulation and hippocampal dysfunction in ME/CFS-related cognitive dysfunction, and to provide insight into potential targeted interventions
About 53% of patients experience arthralgias (joint stiffness) and 22% experience myalgias (muscle pain)
While your body makes it on its own, supplementing with L-Carnitine can give your fat-burning process a little extra boost